Abstract LB-B33: Nonclinical safety evaluation of two distinct second generation variants of anti-CTLA4 monoclonal antibody, ipilimumab, in monkeysKaren Price, Michael J. Graziano, Jean G. Sathish et al.|Molecular Cancer Therapeutics|2018Cited by 11
Abstract 1351: Preclinical characterization of BMS-986288, a novel non-fucosylated (NF) anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) Probody<i>®</i> therapeuticAmy Jhatakia, Nicholas Wilson, Mohammed Nasser et al.|Cancer Research|2024Cited by 2
Improving anti-CTLA-4 therapies through peptide masking and Fc non-fucosylation: preclinical characterization of three novel antibodiesAmy Jhatakia, Tina Cascone, Xin Sun et al.|immuneACCESS|2025Cited by 0